Hospital
The Presbyterian Hospital
The Presbyterian Hospital was paid $33.51M by Medicaid between Jan 2018 and Dec 2024, across 155 billing codes. Its largest line is 99283, emergency room visit (moderate) — 40% of everything it billed.
33Billing provider infoTHE PRESBYTERIAN HOSPITAL
CHARLOTTE, NC 28204
CHARLOTTE, NC 28204
33aNPI1881647204assigned 05/18/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$33.51M
24GClaims641,248
24DCodes billed155
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#18 of 92
Median peer was paid$11.47M
This provider vs. median2.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 92,082 | $4.49M | |
| 2019 | 88,837 | $4.25M | |
| 2020 | 52,145 | $2.45M | |
| 2021 | 87,812 | $4.94M | |
| 2022 | 97,678 | $5.82M | |
| 2023 | 115,681 | $5.66M | |
| 2024incomplete | 107,013 | $5.89M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 40% | 69,433 | 63,727 | $13.45M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 26% | 38,846 | 34,965 | $8.78M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.0% | 22,520 | 21,210 | $1.67M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.4% | 4,837 | 4,159 | $1.15M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.1% | 5,643 | 5,349 | $1.04M |
| J3490 | Unclassified drugs | 1.8% | 189,181 | 78,940 | $598K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.8% | 29,333 | 23,578 | $597K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 12,066 | 10,543 | $581K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.5% | 3,757 | 2,370 | $499K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.4% | 2,451 | 2,320 | $479K |
| 80053 | Comprehensive metabolic panel | 1.4% | 43,092 | 37,844 | $458K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 56,851 | 49,185 | $452K |
143 more codes
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.3% | 2,217 | $427K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,803 | $254K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,394 | $230K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,905 | $159K |
| J2704 | Injection, propofol, 10 mg | <1% | 6,492 | $140K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,041 | $138K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 603 | $124K |
| J2323 | Injection, natalizumab, 1 mg | <1% | 52 | $117K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 235 | $116K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,163 | $94K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,226 | $93K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,335 | $89K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,125 | $83K |
| 87430 | <1% | 5,339 | $83K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,614 | $79K |
| 82728 | <1% | 3,926 | $70K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,782 | $70K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,331 | $63K |
| 54300 | <1% | 199 | $63K | |
| 87070 | <1% | 5,133 | $62K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 127 | $55K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,012 | $55K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,355 | $51K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,945 | $44K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,947 | $43K |
| 81001 | <1% | 11,353 | $42K | |
| 74018 | <1% | 721 | $40K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,633 | $39K |
| G0378 | Hospital observation service, per hour | <1% | 345 | $36K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 47 | $36K |
| 80299 | <1% | 1,644 | $33K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,176 | $32K |
| 81025 | <1% | 3,769 | $31K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 345 | $30K |
| 83550 | <1% | 2,491 | $28K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 553 | $28K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 427 | $27K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 14 | $26K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 109 | $24K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,069 | $23K |
| 82607 | <1% | 1,128 | $22K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 37 | $22K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 260 | $21K |
| 83540 | <1% | 2,494 | $21K | |
| 80143 | <1% | 2,787 | $20K | |
| 84703 | <1% | 1,943 | $19K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,348 | $18K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 747 | $18K |
| 80179 | <1% | 2,781 | $18K | |
| 84484 | <1% | 1,503 | $16K | |
| 85045 | <1% | 3,209 | $15K | |
| 82746 | <1% | 813 | $15K | |
| 54304 | <1% | 56 | $15K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,793 | $14K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 628 | $14K |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 184 | $12K |
| 83735 | <1% | 1,929 | $11K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,026 | $11K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,592 | $10K |
| 83021 | <1% | 268 | $9K | |
| 83690 | <1% | 1,066 | $8K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 37 | $7K |
| 77336 | <1% | 78 | $7K | |
| 83020 | <1% | 341 | $7K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 120 | $7K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 140 | $6K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 674 | $6K |
| 54161 | <1% | 32 | $5K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 264 | $5K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $5K |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 70 | $4K |
| 81003 | <1% | 1,216 | $4K | |
| 54360 | <1% | 12 | $4K | |
| 93798 | <1% | 175 | $4K | |
| 14040 | <1% | 14 | $4K | |
| 64483 | <1% | 52 | $4K | |
| 83921 | <1% | 147 | $4K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 132 | $3K |
| 93296 | <1% | 1,441 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 427 | $3K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 109 | $3K |
| 87581 | <1% | 109 | $3K | |
| 87486 | <1% | 109 | $3K | |
| 85660 | <1% | 326 | $3K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 57 | $3K |
| D0272 | Bitewings - two radiographic images | <1% | 39 | $3K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 169 | $3K |
| 86140 | <1% | 340 | $3K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 124 | $3K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 42 | $3K |
| J3535 | Drug administered through a metered dose inhaler | <1% | 688 | $2K |
| 83615 | <1% | 353 | $2K | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 7,839 | $2K |
| 64450 | <1% | 13 | $2K | |
| D1351 | Sealant - per tooth | <1% | 28 | $2K |
| 92567 | <1% | 122 | $2K | |
| Q3014 | Telehealth originating site facility fee | <1% | 147 | $2K |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 39 | $2K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,366 | $1K |
| 36591 | <1% | 109 | $1K | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 41 | $1K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 55 | $1K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 14 | $896.57 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 41 | $809.20 |
| 96415 | <1% | 18 | $787.34 | |
| D2393 | Resin-based composite - three surfaces, posterior, primary or permanent | <1% | 17 | $786.98 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 13 | $784.47 |
| 80076 | <1% | 99 | $702.40 | |
| 82657 | <1% | 20 | $632.84 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 62 | $624.92 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 279 | $591.71 |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 12 | $507.06 |
| 86304 | <1% | 27 | $456.52 | |
| 99199 | Unlisted special service, procedure or report | <1% | 62 | $395.00 |
| 88300 | <1% | 26 | $379.08 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 2,376 | $378.36 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 25 | $368.16 |
| 84439 | <1% | 62 | $345.83 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $336.16 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12 | $336.16 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 16 | $304.96 |
| 82668 | <1% | 13 | $304.46 | |
| 84100 | <1% | 72 | $243.36 | |
| 82610 | <1% | 13 | $220.22 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 24 | $207.32 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 920 | $204.78 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 47 | $196.83 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 58 | $192.04 |
| 84311 | <1% | 23 | $191.62 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 19 | $171.90 |
| 85027 | <1% | 38 | $168.68 | |
| 85379 | <1% | 12 | $168.18 | |
| 82962 | <1% | 41 | $164.27 | |
| 85610 | <1% | 26 | $109.57 | |
| 82043 | <1% | 12 | $86.52 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 15 | $84.64 |
| 85652 | <1% | 25 | $79.15 | |
| 82570 | <1% | 12 | $77.40 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 280 | $44.51 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 24 | $0.00 |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 0% | 53 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 90 | $0.00 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 31 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFEINOUR, JAMIE (PRESIDENT NH PRESBYTERIAN MEDICAL C)
| Provider | Location | Paid |
|---|---|---|
| The Presbyterian Hospital | Charlotte, NC | $112K |
| The Presbyterian Hospital | Huntersville, NC | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.